Collaborations & Alliances

Amgen, Advaxis in Immunotherapy Alliance

To develop Advaxis' ADXS-NEO investigational cancer treatment

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Amgen and Advaxis, Inc. entered a global agreement for the development and commercialization of Advaxis’ ADXS-NEO, a preclinical investigational cancer immunotherapy. This collaboration will utilize Amgen’s development expertise in immuno-oncology and Advaxis’ MINE (My Immunotherapy Neo-Epitopes) program to develop a customized approach to cancer treatment. Amgen receives exclusive worldwide rights to develop and commercialize ADXS-NEO. Advaxis will receive $40 million upfro...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters